Case 1:22-cv-00252-MSG Document 28-2 Filed 08/01/22 Page 1 of 4 PageID #: 700
`
`Exhibit B
`
`

`

`Case 1:22-cv-00252-MSG Document 28-2 Filed 08/01/22 Page 2 of 4 PageID #: 701
`
`From:
`To:
`Cc:
`
`Subject:
`Date:
`
`McLennan, Mark C.
`Mahaffy, Shaun
`Hurst, James F.; Carson, Patricia A.; Berl, David; Fletcher, Thomas; Harber, Adam; Daralyn Durie ; Eric Wiener;
`Kira A. Davis; Wacker, Jeanna; Blumenfeld, Jack; Egan, Brian P.; #KEModernaSpikevaxService; Genevant Team;
`John Shaw; Karen Keller
`RE: Arbutus v. Moderna
`Monday, August 1, 2022 8:59:22 AM
`
`Shaun,
` 
`Thank you for your email below and for providing “Plaintiffs' Initial Identification of Asserted Patents,
`Accused Products, and Damages Model.” As you are undoubtedly aware,  Plaintiffs cannot
`unilaterally circumvent the Default Standard for Discovery by serving those. Moderna will make its
`disclosures according to any schedule entered by the Court.  Further, nothing in the Default
`Standard or in Judge Goldberg’s Policies and Procedures requires Moderna to produce documents
`by August 16.
` 
`We also see no need for a Rule 26(f) conference while Moderna’s motion is pending and before the
`Court has ordered a Rule 16 conference.
` 
`Best regards,
`Mark
` 
`Mark C. McLennan
`-----------------------------------------------------
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue, New York, NY 10022
`T +1 212 909 3451
`-----------------------------------------------------
`mark.mclennan@kirkland.com
` 
`From: Mahaffy, Shaun <SMahaffy@wc.com> 
`Sent: Thursday, July 28, 2022 9:32 AM
`To: McLennan, Mark C. <mark.mclennan@kirkland.com>
`Cc: Hurst, James F. <james.hurst@kirkland.com>; Carson, Patricia A.
`<patricia.carson@kirkland.com>; Berl, David <DBerl@wc.com>; Fletcher, Thomas
`<TFletcher@wc.com>; Harber, Adam <AHarber@wc.com>; Daralyn Durie
`<DDurie@durietangri.com>; Eric Wiener <EWiener@durietangri.com>; Kira A. Davis
`<kdavis@durietangri.com>; Wacker, Jeanna <jeanna.wacker@kirkland.com>; Blumenfeld, Jack
`<JBlumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>;
`#KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>; Genevant Team
`<GenevantTeam@wc.com>; John Shaw <jshaw@shawkeller.com>; Karen Keller
`<kkeller@shawkeller.com>
`Subject: RE: Arbutus v. Moderna
` 
`Mark,
` 
`We disagree that it is appropriate for Moderna to refuse to begin the process of discussing a
`schedule.  We therefore request again that Moderna join us in the Rule 26(f) discovery planning
`
`Mark, We disagree that it is appropriate for Moderna to refuse to begin the process of discussing a schedule. We therefore request again that Moderna join us in the Rule 26(f) discovery planning conference so that the parties may begin preparing
`
`

`

`Case 1:22-cv-00252-MSG Document 28-2 Filed 08/01/22 Page 3 of 4 PageID #: 702
`
`conference so that the parties may begin preparing the Rule 26(f) report.  Please let us know your
`availability this week for a Rule 26(f) conference.
` 
`Thanks,
`Shaun
` 
`Shaun P. Mahaffy
`Associate | Williams & Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`202-434-5554 | smahaffy@wc.com
` 
`From: McLennan, Mark C. <mark.mclennan@kirkland.com> 
`Sent: Monday, July 25, 2022 8:36 PM
`To: Mahaffy, Shaun <SMahaffy@wc.com>
`Cc: Hurst, James F. <james.hurst@kirkland.com>; Carson, Patricia A.
`<patricia.carson@kirkland.com>; Berl, David <DBerl@wc.com>; Fletcher, Thomas
`<TFletcher@wc.com>; Harber, Adam <AHarber@wc.com>; Daralyn Durie
`<DDurie@durietangri.com>; Eric Wiener <EWiener@durietangri.com>; Kira A. Davis
`<kdavis@durietangri.com>; Wacker, Jeanna <jeanna.wacker@kirkland.com>; Blumenfeld, Jack
`<JBlumenfeld@morrisnichols.com>; Egan, Brian P. <began@morrisnichols.com>;
`#KEModernaSpikevaxService <KEModernaSpikevaxService@kirkland.com>
`Subject: RE: Arbutus v. Moderna
` 
`Counsel,
` 
`We’re in receipt of your email below attaching a draft scheduling order.
` 
`As you know, Moderna’s partial motion to dismiss remains pending before the Court. The parties’
`briefing on Moderna’s motion specifically addressed the extent to which the scope of the case,
`including discovery, would be narrowed should the motion be granted. Accordingly, Moderna does
`not agree to submit a proposed schedule at this early stage while the motion is pending.
` 
`To the extent a schedule is submitted, it should be submitted in accordance with the Rule 16
`conference deadlines when those are set by the Court.
` 
`For future correspondence, please be sure to copy Jack Blumenfeld, Brian Egan, and
`KEModernaSpikevaxService@kirkland.com.   
` 
`Regards,
`Mark
` 
`Mark C. McLennan
`-----------------------------------------------------
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue, New York, NY 10022
`T +1 212 909 3451
`
`

`

`Case 1:22-cv-00252-MSG Document 28-2 Filed 08/01/22 Page 4 of 4 PageID #: 703
`
`Counsel, In view of paragraphs 2 and 4 of Judge Goldberg’s Policies and Procedures guidelines regarding civil matters, Plaintiffs intend to move forward with discovery in the above case. Accordingly, please find attached a draft Scheduling
` 
`
`-----------------------------------------------------
`mark.mclennan@kirkland.com
`
` 
`From: Mahaffy, Shaun <SMahaffy@wc.com> 
`Sent: Wednesday, July 20, 2022 3:19 PM
`To: Wacker, Jeanna <jeanna.wacker@kirkland.com>
`Cc: Hurst, James F. <james.hurst@kirkland.com>; Carson, Patricia A.
`<patricia.carson@kirkland.com>; McLennan, Mark C. <mark.mclennan@kirkland.com>; Berl, David
`<DBerl@wc.com>; Fletcher, Thomas <TFletcher@wc.com>; Harber, Adam <AHarber@wc.com>;
`Daralyn Durie <DDurie@durietangri.com>; Eric Wiener <EWiener@durietangri.com>; Kira A. Davis
`<kdavis@durietangri.com>
`Subject: Arbutus v. Moderna
` 
`Counsel,
` 
`In view of paragraphs 2 and 4 of Judge Goldberg’s Policies and Procedures guidelines regarding civil
`matters, Plaintiffs intend to move forward with discovery in the above case.  Accordingly, please find
`attached a draft Scheduling Order.  Please let us know by July 27 whether Defendants have any
`proposed edits or would like to discuss.
`Thanks,
`Shaun
` 
`Shaun P. Mahaffy
`Associate | Williams & Connolly LLP
`680 Maine Avenue SW, Washington, DC 20024
`202-434-5554 | smahaffy@wc.com
` 
` 
`
`This message and any attachments are intended only for the addressee and may contain information that is
`privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or
`disclose the contents of the message and any attachments. Instead, please delete the message and any attachments
`and notify the sender immediately. Thank you.
`
`The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside
`information, and is intended only for the use of the addressee. It is the property of Kirkland & Ellis LLP or Kirkland & Ellis
`International LLP. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and
`may be unlawful. If you have received this communication in error, please notify us immediately by return email or by email
`to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all attachments.
` 
`
`The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside
`information, and is intended only for the use of the addressee. It is the property of Kirkland & Ellis LLP or Kirkland & Ellis
`International LLP. Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and
`may be unlawful. If you have received this communication in error, please notify us immediately by return email or by email
`to postmaster@kirkland.com, and destroy this communication and all copies thereof, including all attachments.
`
`